Calliditas Therapeutics Ab
Officers & Directors
1. Renee Aguiar-Lucander - CEO: Renee Aguiar-Lucander joined Calliditas Therapeutics AB in 2018 as CEO. She has over 20 years of experience in the pharmaceutical industry, with a particular focus on rare diseases. She previously served as CEO of Swedish Orphan Biovitrum AB. 2. Andrew Udell - CFO: Andrew Udell has been Calliditas Therapeutics AB's CFO since 2018. He has over 20 years' experience in corporate finance and investment banking. Prior to joining Calliditas, he was a Managing Director at Rothschild. 3. Graham Dixon - CSO: Graham Dixon serves as Calliditas Therapeutics AB's CSO. He has more than 20 years of experience in drug discovery and development, with a focus on rare diseases. He previously served as Head of Research at Swedish Orphan Biovitrum AB. 4. Henrik Wagner - CMO: Henrik Wagner joined Calliditas Therapeutics AB as CMO in 2019. He has over 15 years of experience in the pharmaceutical industry, with a focus on clinical development. Prior to joining Calliditas, he was the VP of Clinical Development at Sanofi Genzyme. Directors: 1. Lars Wahlstrem - Chairman: Lars Wahlstrem has been Chairman of Calliditas' Board of Directors since 2018. He has more than 30 years of experience in the pharmaceutical and healthcare industries. 2. Karin Westberg - Director: Karin Westberg has served on Calliditas' Board of Directors since 2017. She has over 20 years of experience in the pharmaceutical industry, with a focus on drug development and commercialization. 3. Merten Steen - Director: Merten Steen has been a Director on Calliditas' Board since 2018. He has more than 20 years of experience in finance and venture capital, and is a Partner with Creandum.
Calliditas Therapeutics Ab currently has 85 employees.
News about Calliditas Therapeutics Ab Key Personnel |
In a significant move to strengthen its financial position, Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) have recently announced the successful refinancing of its existing term loan. The company has secured a Euro 92 million senior secured facility with funds managed by Athyrium Capital Management, LP (Athyrium). This strategic collaboration aims to fuel the future growth prospects of Calliditas in the pharmaceutical industry.
Rising Productivity and Revenue Per Employee:
Calliditas Therapeutics has been experiencing exceptional growth in terms of revenue per employee. Over the trailing twelve months, the company s revenue per employee has reached an all-time high...
|
|
